Genomic Health molecular colon cancer test
This article was originally published in The Gray Sheet
Executive Summary
Genomic Health Jan. 21 announced worldwide availability of its Oncotype Dx colon cancer test, a multigene expression test developed at the firm's CLIA-certified laboratory to assess recurrence risk after surgery in patients with stage II disease